Speakers

A   B   C   D   E   F   G   H   I   J   K   L   M   N   O   P   Q   R   S   T   U   V   W   X   Y   Z

 


Neil Anderson, MD, is an Assistant Professor of Pathology and Immunology in the Division of Laboratory and Genomic Medicine at Washington University School of Medicine.  He is an Assistant Director of Clinical Microbiology and the Director of the Molecular Infectious Disease Laboratory at Barnes Jewish Hospital in Saint Lewis.  Dr. Anderson’s research interests predominantly focus on novel technology and diagnostics, test stewardship, and diagnostic strategies for emerging pathogens.


Noam Auslander, PhD, completed a Bachelor of Science degree in computer science and in biology at Tel Aviv University, Israel. She earned her doctoral degree in computer science from the University of Maryland, with a combined fellowship from the National Cancer Institute, where she studied metabolic dysregulation in cancer via genome scale metabolic modeling, and developed predictors for treatment response and clinical outcome. As a postdoctoral fellow at the National Institute of Biotechnology Information, she developed combined machine learning and evolutionary techniques to model cancer evolution, and to study genomic features of pathogenicity in human viruses.


Michael Bachman, MD, PhD, is an Associate Director of the Clinical Microbiology Laboratory at the University of Michigan. He is a clinical pathologist and physician-scientist with training in clinical microbiology and bacterial pathogenesis. His clinical interests are in molecular diagnostics and diagnosis and infection prevention of multi-drug resistant organisms. In this role, he oversaw the validation and implementation of COVID testing in the clinical laboratory. He is also a principal investigator studying risk factors for Gram-negative bacteremia and Klebsiella pneumoniae infections in hospitalized patients.


Matt Binnicker, PhD is the Director of Clinical Virology and Vice Chair of Practice in the Department of Laboratory Medicine and Pathology at Mayo Clinic. He is a Professor of Laboratory Medicine and Pathology, and serves as the Program Director for the Ph.D. Clinical Microbiology Fellowship at Mayo Clinic. In 2020, Dr. Binnicker began a 2-year term as President of the Pan American Society of Clinical Virology (PASCV). Dr. Binnicker’s research interests focus on the development of rapid molecular methods to diagnose respiratory infections, including the utilization of metagenomic next-generation sequencing. His research has also led to the development of novel, next-generation sequencing methods to identify resistance-associated mutations in cytomegalovirus (CMV), which is an important cause of disease in the transplant population.


Steven Bleyl, MD, PhD, is the Chief Medical Officer at Genome Medical Services. <br><br>Dr Bleyl has served as CMO at Genome Medical since January of 2017 guiding development of the organization’s clinical care processes in its vision to bring genomics to everyday care. Dr Bleyl is a board-certified in medical genetics with a doctorate degree in human genetics and his background spans experience in molecular biology, experimental embryology, clinical care and administrative oversight of clinical services across an integrated health system. He maintains an academic affiliation as an adjunct Associate Professor at the University of Utah where his clinical practice focuses on cardiovascular genetics with a pediatric emphasis. Prior to this role, he directed the Clinical Genetics Institute (CGI) for Intermountain Healthcare where he oversaw the provision of genetic services, implementation of rapid exome sequencing in neonates, deployment of a Genetic Testing Stewardship Program and development of a system-wide infrastructure for storage and use of genomic data.


Kelly Bolton, MD, PhD, is an assistant attending on the leukemia service at Memorial Sloan Kettering Cancer Center. She has a PhD in genetic epidemiology and is a medical oncologist. Her research surrounds clonal hematopoiesis in cancer patients including the influence of oncologic therapy and the risk of therapy-related myeloid neoplasms. She leads the clonal hematopoiesis clinic at Memorial Sloan Kettering Cancer Center.


Susan Butler-Wu


Jose Manuel Collados leads ABB Robotics for Healthcare team, new venture from ABB Robotics into Healthcare, from Houston with the aim to combine ABB large industry experience and technology with Healthcare experts to support safety, quality, productivity and patient care in various Healthcare operations, like laboratory and pharmacy automation, supply chain, logistics and hazarous tasks. Jose Manuel has been working 22 years in ABB where he could gain experience in all aspects of technology engineering, project management and sales for fields like robotics, power systems, power electronics and motion. He could also lead or participate in new ventures from ABB in renewable energy (wind and solar), traction and robotics. 


Garry R. Cutting, MD, is the Aetna/U.S. Healthcare Professor of Medical Genetics, Pediatrics and Medicine in the McKusick-Nathans Department of Genetic Medicine of the Johns Hopkins University School of Medicine. He has been the Medical Director of the DNA Diagnostic Laboratory of Johns Hopkins Genomics since 1995.  He directed the Medical Genetics Residency Program at Hopkins from 1995 to 2004 and Clinical Genetic Laboratory Training Program from 1995 to 2018. As Editor of the journal Human Mutation, Dr. Cutting oversees the review and publication of manuscripts reporting the mechanism, distribution and phenotype consequences of variation in our genomes. Dr. Cutting’s primary research interests lie in the interpretation of DNA variation and their effect upon human phenotypes. Dr. Cutting’s lab focuses on the effect of common and rare variants in the CFTR gene that cause the single gene disorder cystic fibrosis (CF).  His team operates the CFTR2 database, a resource composed of clinical and genetic data on almost 90,000 individuals with CF world-wide.  His laboratory also studies the effect of clinically approved and novel modulators upon CFTR protein bearing disease-causing variants.  Dr. Cutting’s laboratory is also leader in the identification and characterization of genetic modifiers of CF.  His group is currently collaborating with teams at UNC and UW, Seattle to identify common and rare modifier variants of disease severity by whole genome sequencing.  Dr. Cutting is the recipient of the Paul di Sant’Agnese Distinguished Scientific Achievement Award from the Cystic Fibrosis Foundation and a MERIT award from the National Institutes of Health. He has published more than 180 peer-reviewed articles. Dr. Cutting was elected to the Society of Pediatric Research (1992), the American Society of Clinical Investigation (1995) and the Association of American Physicians (2017).


Sanchita Das, MD, D(ABMM), received her medical degree from Calcutta University and completed residency in Medical Microbiology from Postgraduate Institute of Medical Education and Research, Chandigarh, India. Her professional and research interests include development of diagnostic assays for infectious diseases and using novel methods to understand the pathogenesis and epidemiology of infections. She is the Acting Director of Molecular Diagnostics Laboratory at the National Institutes of Health, Clinical Center.


Sandeep Dave, MD, MS is the Professor of Medicine and Director of Cancer Genetics and Genomics Program at the Duke Cancer Institute of Duke University. Sandeep Dave received his MS, MD, and MBA at Northwestern University. He completed his clinical and post-doctoral training at Northwestern and the National Institutes of Health (NIH) in Bethesda, Maryland. With a background in oncology and genomics, Dr. Dave is Professor of Medicine at Duke University in Durham, North Carolina. He is Director of the Cancer Genetics and Genomics Program at Duke. His research program is focused on the genetic mechanisms underlying lymphomas. Dr Dave’s work has been published in many peer-reviewed journals including Cell, Nature Genetics, Blood, and the New England Journal of Medicine. He has been the recipient of many honors and awards including the Research Scholar Award from the American Cancer Society and a career award from the Doris Duke Foundation. He was elected to the American Society of Clinical Investigator, the honor society of physician scientists and the Scientific Advisory Board of the Lymphoma Research Foundation. Dr Dave is a member of the American Society of Hematology and the American Society of Clinical Oncology.


Richard Davis, PhD is the Regional Director of Microbiology for Providence Health Care in Eastern Washington. He completed his Clinical Microbiology Fellowship at the University of Utah/ARUP Laboratories and is a Diplomate of the American Board of Medical Microbiology. Dr. Davis is a certified Medical Laboratory Scientist and received his PhD from the University of Iowa studying the immune response to the tropical parasite Leishmania. He gives lectures on infectious disease diagnostics for the Providence Medical Laboratory Science program and WSU Medical School. He shares daily pictures on Twitter of cultures and pathogens from the clinical microbiology lab under @RichDavisPhD.


Josh Deignan, PhD, FACMG, is an Associate Clinical Professor in the Department of Pathology and Laboratory Medicine in the David Geffen School of Medicine at UCLA. He is one of the Associate Directors of the UCLA Molecular Diagnostics Laboratories, specializing in the areas of molecular genetics and genomics. He performed his undergraduate work in Genetics at the University of California, Davis, and he received his Ph.D. in Pathology and completed his medical genetics fellowship training at UCLA. He is board-certified by the American Board of Medical Genetics and Genomics in Clinical Molecular Genetics and Genomics and is licensed by the state of California as a Clinical Genetic Molecular Biologist (CGMB).       


Carlos Del Rio, MD


Amy DeZern, MD, MHS primary clinical and research interests are focused on bone marrow failure disorders. She has expertise in the diagnosis and treatment of myelodysplastic syndromes (MDS), aplastic anemia (AA), paroxysmal nocturnal hemoglobinuria (PNH), and other bone marrow failure syndromes as well as acute leukemias. She sees clinic patients weekly with these diagnoses as well as patients in need of bone marrow transplants for the same disorders. Dr. DeZern greatly enjoys taking care of patients with bone marrow failure and hematologic malignancies, and is dedicated to improving the care and outcomes of patients with these conditions. To that end, she is an active clinician scientist who specializes in clinical studies of diagnostics and therapeutics for marrow failure. She is the principal investigator of several clinical trials treating patients with severe aplastic anemia using a specialized bone marrow transplant regimen at Johns Hopkins as well as the PI of multiple other study protocols for novel therapeutics in MDS. Her work has resulted in multiple publications in the scientific literature and presentations at national meetings. She is also involved with the Aplastic Anemia and MDS International Foundation and is the local PI of the MDS Clinical Research Consortium. Additionally, she is the Deputy Chair of the National MDS Study.


Daniel Diekema is a Professor of Internal Medicine and Pathology at the University of Iowa Carver College of Medicine. He is the director of the Division of Infectious Diseases, associate director of the Clinical Microbiology Laboratory, and associate hospital epidemiologist at the University of Iowa Healthcare. Dr. Diekema’s clinical and research interests include the role of the diagnostic laboratory in infection prevention and antimicrobial stewardship. He has served on national committees that establish standards in clinical microbiology and infection prevention, including the Clinical and Laboratory Standards Institute (CLSI) and the CDC’s Healthcare Infection Control Practices Advisory Committee (HICPAC), and he is a past-president of the Society for Healthcare Epidemiology of America (SHEA). 


Maria Figueroa, MD received her MD from Universidad del Salvador, School of Medicine in Buenos Aires, Argentina in 1997 and, She trained as a hematologist at the Institute for Hematological Research “Mariano Castex” from the National Academy of Medicine in Buenos Aires, where she later joined the Malignant Hematology Department. In 2004 Dr. Figueroa joined Dr. Ari Melnick’s laboratory in New York where her research focused on the characterization of epigenetic deregulation in myeloid malignancies, particularly Acute Myeloid Leukemia and Myelodysplastic Syndromes. In 2011 Dr. Figueroa started her independent career as an Assistant Professor at the University of Michigan Medical School, where she continued her work in the field of epigenetic regulation of normal and malignant hematopoiesis. In September 2016 she was recruited as Associate Professor to the University of Miami Miller School of Medicine, Dept. of Human Genetics. She also serves as the Co-Leader Cancer Epigenetics Research Program and Assistant Director for Translational Research for the Sylvester Comprehensive Cancer Center. Throughout her career, Dr. Figueroa has been the recipient of scholar awards from the SASS Foundation for Cancer Research, the American Society of Hematology, The Leukemia and Lymphoma Society and the Doris Duke Charitable Foundation. The Figueroa lab studies the role of epigenetic modifications in transcriptional regulation during normal and malignant hematopoiesis. The lab’s focus is mainly on how changes in normal chromatin patterns occur during malignant transformation and how these changes may contribute to the leukemogenic process and disease phenotype. They use a combination of computational approaches based on genome-wide next generation sequencing data as well as in vitro and in vivo modeling to determine the consequences of the epigenetic abnormalities that they identify. In addition, they seek to harness the power of epigenomics for the development of molecular biomarkers predictive of therapeutic response and clinical outcome. 


Thomas Gajeweski, MD, PhD


Omai Garner, PhD is an Associate Clinical Professor and Director of Clinical Microbiology in the UCLA Health System. He received his PhD from UC San Diego in Biomedical Sciences. He was a Postdoctoral Clinical Microbiology CPEP Fellow in the Department of Pathology at UCLA, and a former McNair Scholar. Dr. Garner is Board Certified by the American Board of Medical Microbiology. Dr. Garner's research focuses on novel Point of Care Devices for infectious disease diagnosis in the developing world.


Marios Giannakis, MD, PhD is an Assistant Professor of Medicine at Harvard Medical School, a translational researcher and a physician in the Gastrointestinal Cancer Center in the Division of Medical Oncology at Dana-Farber Cancer Institute in Boston, MA.  He received his medical and doctoral degrees from Washington University in Saint Louis and completed his residency in internal medicine at Brigham and Women’s Hospital and fellowship training in medical oncology and hematology at the Dana-Farber Cancer Institute.  As a physician-scientist, Dr. Giannakis specializes in the treatment of gastrointestinal cancers and is an independent investigator whose laboratory and research focuses on the pathogenesis of colorectal cancer and the development of novel targeted and immune-based therapies for patients with this disease. 


Christopher Gilbert, DO, MS, FCCP is an Interventional Pulmonologist currently at Swedish Cancer Institute in Seattle, Washington. He completed his Pulmonary and Critical Care Medicine fellowship at Thomas Jefferson in Philadelphia followed by an Interventional Pulmonology fellowship at Johns Hopkins in Baltimore. His clinical and research interests include lung cancer diagnosis and staging, management of central airway obstruction, and malignant pleural disease. 


William A Glover II, PhD received his PhD in Molecular Microbiology and Immunology from the Johns Hopkins Bloomberg School of Public Health in 2010. He completed a post-doctoral Fellowship in Clinical and Public Health Microbiology at the University of Washington Medical Center in Seattle, WA. He is a diplomate of the American Board of Microbiology and is active in the American Society for Microbiology and the Association of Public Health Laboratories. Currently, he is an Assistant Laboratory Directory at the North Carolina State Laboratory of Public Health where he oversees the Infectious Diseases Units. Throughout his scientific career he has been involved in teaching and mentoring others. 


William Hahn, MD, PhD is the William Rosenberg Professor of Medicine in the Department of Medical Oncology at the Dana-Farber Cancer Institute and Harvard Medical School and an Institute Member of the Broad Institute of MIT and Harvard. He is the Chief Scientific Officer at the Dana-Farber Cancer Institute. Dr. Hahn has made numerous discoveries that have informed our current molecular understanding of cancer and have formed the foundation of new translational studies. Dr. Hahn and his colleagues helped demonstrate that activation of the reverse transcriptase telomerase plays an essential role in malignant transformation. This observation provided the means to create novel experimental model systems to identify and characterize the cooperative genetic interactions that lead to malignant transformation. Together with his colleagues at the Broad Institute, he helped develop genome scale tools and technology to perform somatic cell genetics in human cells. His laboratory has pioneered the use of integrated functional genomic approaches to identify and validate cancer targets. The tools, models and approaches that his laboratory has developed are widely used worldwide to discover and validate molecularly targeted cancer therapies. Dr. Hahn and his collaborators are now engaged in clinical trials testing whether inhibition both of new oncogenes or synthetic lethal partners identified by these approaches will lead to clinical responses. Dr. Hahn has served as the President of the American Society for Clinical Investigation and has been elected to the Association of American Physicians. Dr. Hahn has been the recipient of the Wilson S. Stone Award from M.D. Anderson Cancer Center for outstanding research in cancer (2000), a Howard Temin Award from the National Cancer Institute (2001), the Ho-Am Prize in Medicine (2010), the Richard and Hinda Rosenthal Award from AACR (2015) and the Claire and Richard Morse Award (2019).


Justin Hammerling, MBA is the AVP of Innovations and manages the daily operation of the ProMedica Innovations Center and the ProMedica Innovations team. Working in partnership with the executive management team, Justin creates leading-edge solutions in support of ProMedica’s mission and goals while providing best-in-class services and expert resources to life science entrepreneurs and inventors. An expert strategist and accessible leader, Justin also serves as President for Kapios Health, a HIT company. In this position, Justin is known for driving growth and profitability, as well as his expertise in developing and delivering technology solutions for hospitals, health systems and medical practices. Justin understands healthcare structures and the complimentary function of leading-edge technology in healthcare. He is dedicated to working with inventors to develop their ideas and help them successfully market their products to the medical marketplace. Justin earned his BA and Masters degrees from the University of Colorado, as well as an MBA from the University of Toledo. Justin was recognized by Modern Healthcare for being one of the nation’s top 25 innovators in healthcare for 2019.


Amanda Harrington, PhD, D(ABMM)


D. Jane Hata, PhD, D(ABBM) is the Director of the Clinical Microbiology and Molecular Virology Laboratories at Mayo Clinic in Florida, and Assistant Professor of Laboratory Medicine and Pathology, Mayo Clinic Alix School of Medicine. Her responsibilities include technical oversight of the Bacteriology and Molecular Virology Laboratories, including microbiological testing for the Mayo Clinical Laboratories reference service. She is a past member of the Microbiology Resource Committee for the College of American Pathologists, and the Committee on Postgraduate Educational Programs for the American Society for Microbiology. Dr. Hata received her Ph.D. from the University of Missouri – Columbia, and completed a Fellowship in Clinical Microbiology at the Mayo Clinic, Rochester, Minnesota. Her research interests include mechanisms of antimicrobial resistance, diagnosis of fungal infections, and development of molecular diagnostic techniques for clinical laboratory.


Madhuri Hegde, PhD is the Vice President and Chief Scientific Officer of Global Laboratory Services at PerkinElmer where she is responsible for ten clinical laboratories around the world. She also holds appointments of Adjunct Professor of Pediatrics at both Emory University and Georgia Tech. Dr. Hegde is a board-certified molecular geneticist with over 150 peer-reviewed publications throughout her career. She has over 20 years’ experience in clinical diagnostics, which includes laboratory administration, management, developing tools for comprehensive “omicsâ€? analysis and interpretation for genomic variation, and consultation with molecular diagnostic companies. She has served on several FDA panels related to NGS and other molecular technologies. She serves on serves on several CAP and ACMG committees involved in writing guidelines for clinical laboratory. She has served on CAP Molecular Genetics committee overseeing proficiency testing challenges for molecular assays including NGS. The focus of her clinical work has been the development and implementation of high-throughput strategies for discovery and clinical testing for rare disorders using next generation sequencing (NGS), robotics, clinical exome and genome sequencing, and oligonucleotide array platforms. Her more recent work is focused developing strategies for offering clinical genome sequencing for newborns and adult (neurology) populations. Her research work is focused on neuromuscular disorders and understanding the impact rare variant burden in genetic diseases. Before joining PerkinElmer Genomics to build a global laboratory network focused on clinical ‘Omics, she was the Executive Director of Emory Genetics Laboratory and Professor of Genetics and Pediatrics at Emory University. She received a B.Sc. and a M.Sc. from the University of Bombay, India, and a Ph.D. from the University of Auckland, New Zealand. She completed post-doctoral studies at Baylor College of Medicine and is a diplomate of American Board of Medical Genetics and Fellow of the American College of Medical Genetics and Genomics. 


Nicole Hoppman, PhD received her Ph.D. in Human Genetics from the University of Maryland School of Medicine. She then completed fellowships in both clinical molecular genetics and clinical cytogenetics at Mayo Clinic and is currently a board-certified cytogeneticist/molecular geneticist at Mayo Clinic. Dr. Hoppman is an Associate Professor of Laboratory Medicine and Pathology and is also the Program Director of the Laboratory Genetics and Genomics Fellowhsip. Her interests include the evaluation and implementation of novel molecular technologies to increase diagnostic yield for both constutitional disorders and hematologic malignancies.


Javeed Iqbal, MS, PhD is the Associate Professor of the Department of Pathology and Microbiology at the University of Nebraska Medical Center, Omaha, NE. His research focus is on Peripheral T-cell lymphoma. To understand molecular mechanism of lymphomagenesis. To develop molecular classifiers using genomic approaches.

 


Gail Javitt


Sabah Kadri, PhD, is the Director of Bioinformatics and Assistant Professor of Pathology at Lurie Children’s Hospital of Chicago, where she leads efforts in bioinformatics for precision medicine in pediatrics, including setting up clinical genomics tools and pipelines in the cloud. Her team designs bioinformatics and machine learning solutions for pediatric somatic and germline testing using panel and whole genome sequencing (WGS). She was previously the Director of Bioinformatics at the Genomic and Molecular pathology division at the University of Chicago, where she led the design, implementation and support of clinical testing for adult oncology including development of novel tools and pipelines for cutting-edge next generation sequencing (NGS) applications, such as UCM-OncoPlus, a comprehensive diagnostic 1200 gene panel that can perform variant calling, copy number, gene-fusion, and MSI detection. With a background in computer engineering, Dr. Kadri earned a PhD in Computational Biology at Carnegie Mellon University (Pittsburgh, PA) using an interdisciplinary approach to study small noncoding RNAs in echinoderm development. In 2012, she joined the Lander Lab at the Broad Institute, where she continued working on noncoding RNA populations such as large non-coding RNAs (lincRNAs) and end-RNASeq technologies. Dr. Kadri has significant expertise in NGS technologies and her research work has been focused on using the power of NGS methods innovatively in the field of computational genomics.


Tess Karre, MD earned her medical degree at Creighton University and received her Anatomic and Clinical Pathology residency training at Penrose-St. Francis in Colorado Springs.  Follwing residency, she completed a Medical Microbiology fellowship at the Mayo Clinic.  She is the Medical Director of Microbiology and Serology for Methodist and Children's Hospitals in Omaha, NE and oversees all of the major areas of microbiology including aerobic and anaerobic bacteriology, mycology, mycobacteriology, parasitology, virology, serology, and molecular infectious diseases.   As a practicing pathologist in a community setting, Dr. Karre also participates in the Anatomic Pathology service and has a special interest in infectious diseases pathology.


Cihan Kaya, PhD, is a lead bioinformatics scientist in the Molecular and Genomic Pathology Laboratory, Department of Pathology, University of Pittsburgh Medical Center. He received his B.S. in chemical engineering and physics from Bogazici University, Istanbul, Turkey and a Ph. D. in computational biology at University of Pittsburgh. Before joining Molecular and Genomic Pathology lab, Dr. Kaya worked on various projects in computational structural biology, mathematical modeling of biological processes and computational neuroscience. His multi-scale 3D model of dopaminergic neurons was the one of the major accomplishment of National Center for Multiscale Modeling of Biological Systems. Dr. Kaya’s research interests span medical informatics, bioinformatics, machine learning and data science with applications in integration multiomic analysis of multiscale clinical data sets, large scale sequencing and biomarker discovery. He is working on deployment of scalable NGS testing on modern deployment infrastructures.


Stephen F. Kingsmore, MD is President/CEO of the Rady Children’s Institute for Genomic Medicine (RCIGM), San Diego, which is implementing pediatric genomic medicine on an unprecedented scale. Previously he was the Dee Lyons/Missouri Endowed Chair in Genomic Medicine at the Univ. of Missouri-Kansas City and Director of the Center for Pediatric Genomic Medicine at Children’s Mercy Hospital, Kansas City. He has been the President/CEO of the National Center for Genome Resources, Santa Fe, New Mexico, Chief Operating Officer of Molecular Staging Inc., Vice President of Research at CuraGen Corporation, and Assistant Professor at the University of Florida’s School of Medicine. Dr. Kingsmore received BSc, MB, ChB, BAO and DSc degrees from the Queen’s University of Belfast. He did residency in internal medicine and fellowship at Duke University Medical Center. He is a fellow of the Royal College of Pathologists. He was a MedScape Physician of the year in 2012, and received the 2013 Scripps Genomic Medicine award and 2013 ILCHUN prize of the Korean Society for Biochemistry and Molecular Biology. TIME magazine ranked his rapid genome diagnosis one of the top 10 medical breakthroughs of 2012. In 2018, RCIGM set a Guinness World Record for fastest genomic diagnosis (19 hours) entirely using whole genome sequencing and artificial intelligence.


Matthew Lebo, PhD 


Mia A. Levy, MD, PhD is the Director of the Cancer Center at Rush University Medical Center and the System Vice President for Cancer Services at Rush System for Health.  She is an Associate Professor of Medicine in the Division of Hematology and Oncology and a practicing medical oncologist specializing in the treatment of breast cancer and precision oncology.  <br><br>Dr. Levy’s research mission is to develop and disseminate learning cancer systems that deliver data and knowledge driven clinical decision support across the continuum of cancer care and research.   To accomplish this, she applies biomedical informatics and implementation science methods to real-world problems in healthcare delivery systems.  As the director of the Cancer Center at Rush University Medical Center, Dr. Levy is leading efforts to create a learning healthcare system as part of the strategic direction for continuous discovery and improvement of cancer outcomes embedded into routine clinical practice.  Precision cancer medicine implementation continues to be a driving use case for the learning systems framework, combining integration of genomic data into clinical workflows within the electronic health record, knowledge driven clinical decision support systems driven by the My Cancer Genome knowledge base, and infrastructures for secondary use of data for discovery both locally and as part of international data consortium.


Dennis Lo, FRS is the Li Ka Shing Professor of Medicine of The Chinese University of Hong Kong (CUHK). His research interests focus on the biology and diagnostic applications of cell-free nucleic acids in plasma. In particular, he discovered the presence of cell-free fetal DNA in maternal plasma in 1997 and has since then been pioneering non-invasive prenatal diagnosis using this technology. This technology has been adopted globally and has created a paradigm in prenatal medicine. He has also made many innovations using circulating nucleic acids for cancer detection, including the screening of early stage nasopharyngeal cancer. In recognition of his research, Professor Lo has been elected as Fellow of the Royal Society, Foreign Associate of the US National Academy of Sciences, Fellow of The World Academy of Sciences (TWAS) and Founding Member of the Academy of Sciences of Hong Kong. 


James Lu, MD, PhD is a co-founder and Chief Science Officer at Helix. Helix’s mission is to empower every person to improve their life through DNA. Helix is accelerating the integration of genomic data into clinical care and broadening the impact of large-scale population health programs by providing comprehensive expertise in DNA sequencing, bioinformatics, and individual engagement. Powered by our proprietary Exome+® assay—a panel-grade exome enhanced by more than 300,000 informative non-coding regions—Helix offers health systems a scalable solution which enables the discovery of medically relevant, potentially life-saving, genetic information. Additionally, Helix offers a suite of DNA-powered products for continued individual engagement and discovery.  At Helix, James has responsibility for the scientific teams which includes bioinformatics, laboratory operations, regulatory, quality, translational research and policy teams. Prior to Helix, James was a faculty member at Duke University where he focused on translational genomics and machine learning methodologies for electronic medical records. James has also explored a broad range of research topics in population genetics, Mendelian genomics, and computational psychiatry and has published dozens of papers in journals such as Nature, the New England Journal of Medicine and the Journal of Machine Learning Research.  Earlier in his career, James was a  Lean Six Sigma Black Belt at Merck Pharmaceuticals, a global biopharma company, and an Associate at Devon Park Bioventures, a Philadelphia based healthcare venture capital firm. James holds an M.D. and Ph.D. from Baylor College of Medicine, where he was a member of the Alpha Omega Alpha Honor Society. He also received a B.S. and M.S. in Chemical Engineering from Stanford University.


Elizabeth Marlowe, PhD is currently the Scientific Director and Head of R&D West for Quest Diagnostics Infectious Diseases. She received her Ph.D. from the University of Arizona in 1999 and completed a Clinical/Public Health Microbiology Postdoctoral Fellowship in 2001 at the UCLA David Geffen School of Medicine. After her fellowship, she continued as an Adjunct Professor and Research Coordinator at the Wadsworth Anaerobe Laboratory where her research focused on the microbiome of the autistic gut and the role of toxin producing anaerobes. In 2002, Dr. Marlowe joined Gen-Probe with her primary research in the development of rapid molecular diagnostics for infectious diseases. Her team conducted some of the initial prototype assay feasibility work on the Panther Fusion System. From 2005 – 2016 she provided laboratory leadership within the Kaiser Permanente Regional Laboratories in both Southern California, as the Assistant Director, and Northern California, as Director of Microbiology. She also provided oversight for the translational research program that included participation in > 10 clinical trials. From 2016-2019, she held the position of Global Director of Medical Affairs at Roche Molecular Systems where she supported several product launches including the cobas CT/NG, TV/MG, MTB, MAI & RIF/INH assays. She is a diplomat of the American Board of Medical Microbiology, past-president for So Cal ASM, past editor for the Clinical Microbiology Newsletter and an inaugural member to the Council on Microbial Sciences for ASM. She has served as a member of CLIAC, the federal advisory committee for CLIA. Her research areas of interest are focused on the translation of new infectious disease diagnostics for use in evidence-based research for clinical microbiology practice. 


Raquel Martinez, MBA, PhD


Steve Miller, MD, PhD is director of the clinical microbiology laboratory at the University of California San Francisco in the department of Laboratory Medicine. He trained at the Albert Einstein College of Medicine and is interested in the use of molecular methods for diagnosis and monitoring of clinical infectious disease, particularly in immunocompromised and transplant patients. He oversees the development and validation of unbiased metagenomic sequencing for pan-pathogen detection in the clinical laboratory, enabling a precision medicine approach for infectious disease.


Stephanie Mitchell, PhD is the Medical Director of the Clinical Microbiology Laboratory at UPMC Children’s Hospital of Pittsburgh, Assistant Medical Director of the Clinical Microbiology Laboratory at UPMC Presbyterian and Assistant Professor of Pathology, School of Medicine and Infectious Disease and Microbiology, Graduate School of Public Health at University of Pittsburgh. Dr. Mitchell is also a Diplomate of the American Boards of Medical Microbiology. The laboratories under Dr. Mitchell’s direction are full-service, covering bacteriology, virology, parasitology and mycology, and serve adult and pediatric patients, including large transplant and cancer treatment centers. She received her doctorate in Molecular Microbiology from Tufts University. Following her graduate training, she completed a post-doctoral fellowship-training program in Medical and Public Health Microbiology at the University of Pennsylvania. Dr. Mitchell is interested in the performance and implementation of novel molecular diagnostics, including next generation sequencing, and antimicrobial susceptibility testing in the clinical laboratory, in addition to the clinical utility of new molecular assays and their impact on patient care. Dr. Mitchell’s current research is in the development of diagnostic assays using next generation sequencing, novel antimicrobial susceptibility testing and molecular diagnostic outcomes studies.


William Muller, MD, PhD, primary clinical interest is in infections in immunocompromised patients, generally stem cell and solid organ transplant recipients. He is site PI for numerous clinical trials involving anti-infectives, in both the immunocompromised population and in other pediatric infections. He has also worked on pathogenesis of viral diseases in pediatrics focusing on host-pathogen interactions, including models of neurologic disease due to herpes simplex virus in newborns. Lastly, he has been the Program Director for the Pediatric Infectious Diseases Fellowship Program since 2013.


Kimberlee Musser, PhD is the Clinical Director for the NYSDOH Wadsworth Center’s David Axelrod Institute and the Chief of Bacterial Disease overseeing the Bacteriology and Mycobacteriology testing programs. She has overseen bacterial public health reference testing, surveillance and outbreak investigations for more than 20 years. Dr. Musser received a BA in Biology from Clark University followed by a PhD in Biomedical Science from Albany Medical College and a Centers for Disease Control (CDC) Emerging Infectious Diseases postdoctoral fellowship hosted at the Wadsworth Center. <br>Dr. Musser is an author on >70 manuscripts, 4 book chapters, and has given numerous invited seminars at local, national and international meetings.  She has also mentored > 30 students and training fellows. Her laboratory has developed and validated dozens of laboratory-developed tests including real-time PCR assays, MALDI-TOF Mass Spectrometry, pyrosequencing and most recently whole-genome sequencing.


Rakesh Nagarajan, MD, PhD is a founder and the Executive Chairman of the Board at PierianDx. He is trained as a physician-scientist with deep experience in molecular biology, molecular laboratory workflows and techniques. His multiple informatics subspecialties include bioinformatics, biospecimen informatics, clinical trials informatics, and medical informatics. He currently serves on the College of American Pathologists (CAP) Molecular Oncology Committee and the Next-Generation Sequencing (NGS) Project Team and is a molecular pathology specialty inspector for the CAP. He is also an Adjunct Associate Professor at the Washington University School of Medicine Department of Pathology & Immunology. Dr. Nagarajan was formerly an Associate Professor at the Washington University School of Medicine (WUSM) Department of Pathology & Immunology and Genetics and directed the Alvin J. Siteman Cancer Center Bioinformatics Core and the Washington University Clinical and Translational Science Award (CTSA) Biomedical Informatics Program. From 2003-2015, Dr. Nagarajan and his group developed and supported broad biomedical informatics infrastructure to facilitate clinical and translational research and to support clinical genomic testing. With more than 50 peer-reviewed publications, his laboratory collaborated on numerous clinical and genomic projects by leading in silico analyses of diverse complex disease data sets.


Debra Palazzi, MD, MEd is Professor of Pediatrics at Baylor College of Medicine in Houston, TX. She received her medical degree from the University of North Carolina School of Medicine. She completed her pediatric residency at Carolinas Medical Center and her pediatric infectious diseases fellowship at Baylor College of Medicine in Houston, TX. She is the Medical Director of the Antimicrobial Stewardship Program at Texas Children's Hospital and participates in national antimicrobial stewardship educational and research activities including the Pediatric Infectious Diseases Society's (PIDS) Pediatric Committee on Antimicrobial Stewardship and the Sharing Reports for Pediatric Stewardship (SHARPS) Collaborative. Dr. Palazzi has a strong interest in medical education. She is Program Director of the Pediatric Infectious Diseases Fellowship Program at Baylor College of Medicine. She received a Master of Education in teaching with an emphasis in the health sciences through the University of Houston. She chairs the PIDS Education Committee and is Deputy Editor of the American Academy of Pediatrics Pediatric Review and Education Program (PREP) for Infectious Diseases and Co-Chair of the PREP ID Course Planning Committee. Dr. Palazzi is Associate Editor of JAMA Pediatrics and the Journal of the Pediatric Infectious Diseases Society.


Sharon Plon, MD, PhD is a board-certified medical geneticist and a longstanding cancer genetics researcher including the discovery of new cancer susceptibility genes and the implementation of genomic testing in medicine.  Dr. Plon is a Professor at Baylor College of Medicine in the Departments of Pediatrics/Hematology-Oncology, Molecular and Human Genetics and Human Genome Sequencing Center. Drs. Plon and D. William Parsons were principal investigators of the NHGRI/NCI-funded BASIC3 clinical trial on the incorporation of exome sequencing into the care of newly diagnosed childhood cancer patients and this study is now being expanded into diverse patient populations across Texas (KidsCanSeq trial). Since 2013, Dr. Plon has served as one of the Principal Investigators of the Clinical Genome (ClinGen) Resource and chairs the ClinGen hereditary cancer effort. ClinGen is an international effort with over 1400 investigators from 35 different countries. Dr. Plon currently co-chairs the germline reporting effort of the national NCI/COG Pediatric MATCH Precision Oncology trial. Dr. Plon is also working closely with Dr. Philip Lupo on a population-based study to understand the association between birth defects and cancer risk in children. Dr. Plon is a member of the NIH Human Genome Research Advisory Council.


Pedram Razavi, MD, PhD


Scott Rodig, MD, PhD, is a practicing hematopathologist and molecular pathologist at Brigham & Women's Hospital, Director of the Tissue Biomarker Laboratory of the Center for Immuno-Oncology at the Dana-Farber Cancer Institute, and Professor of Pathology at Harvard Medical School.  Dr. Rodig received his MD and PhD (Immunology) at Washington University in St. Louis in 1998.  He completed his residency and post-graduate training at Brigham & Women's Hospital and joined the faculty in 2003.  Dr. Rodig's investigational efforts involve the development of novel diagnostic assays to capture the activity of essential oncogenic signaling pathways in human cancer using primary tissue samples. Most recently, these efforts have focused on defining immune responses within the tumor microenvironment to better guide immunotherapy.  In 2018, Dr. Rodig initiated ImmunoProfile, a CLIA-certified multiplex staining and image analysis assay to quantify PD-1 and PD-L1 expression in clinical samples for patients seen at the Dana-Farber Cancer Institute.


Mark Routbort


Somak Roy


Sinchita Roy-Chowdhuri, MD, PhD is an Associate Professor at The University of Texas MD Anderson Cancer Center (MDACC) in Houston, TX, specializing in cytopathology and molecular pathology.  She is currently the Medical Director of the Molecular diagnostic Laboratory (Solid Tumors) and the Director of Molecular Cytopathology at MDACC.  Her interests include pulmonary cytopathology, molecular diagnostics in solid tumors, and the application of ancillary studies and molecular diagnostics in cytopathology.  Dr. Roy-Chowdhuri has presented several educational courses at national and international meetings and published numerous research articles, reviews, and books in the field of cytopathology and molecular pathology. She serves as the Associate Editor for Cancer Cytopathology and the Archives of Pathology & Laboratory Medicine. She is a committee member in several national societies and is the Chair on the CAP guideline committee for the collection and handling of thoracic specimens for molecular testing. Dr. Roy-Chowdhuri serves as a mentor to pathology trainees and can be frequently seen participating in pathology education on social media. You can follow Dr. Roy-Chowdhuri on her Facebook page, @SinchitaRoyMDPhD and on Twitter @Sinchita_Roy


Orit Rozenblatt-Rosen, PhD is the senior director of single cell genomics at the Broad Institute of MIT and Harvard, where she is also scientific director of the Klarman Cell Observatory. In this role, she works on the scientific planning, organization, and execution of the Klarman Cell Observatory projects, collaborations, and activities. The Klarman Cell Observatory aims to systematically chart cellular circuits in mammalian cells and tissues. The Observatory builds on cutting-edge experimental and computational technologies as well as collaborations that span diverse scientific disciplines. Rozenblatt-Rosen is also the lead scientist at the Broad for the international Human Cell Atlas Initiative. The Human Cell Atlas aims to create comprehensive reference maps of all human cells as a basis for both understanding human health and treating disease. Rozenblatt-Rosen, who joined the Klarman Cell Observatory in 2012, is also an institute scientist at the Broad and has a background in cancer research, epigenetics, systems biology, genomics, and single-cell genomics. Rozenblatt-Rosen helped develop and implement systematic pipelines for genomic profiling and analysis of single cells from freshly dissected tumors. In 2016 Rozenblatt-Rosen received the Broad Excellence Award in Science. As a research scientist at the Dana-Farber Cancer Institute, Rozenblatt-Rosen led a team of experimental and computational biologists. Her team performed systematic analyses of host network perturbations induced by DNA tumor viruses to help interpret cancer genomes. Previously, Rozenblatt-Rosen was a postdoctoral fellow and instructor in the laboratory of Broad institute member Matthew Meyerson at the Dana-Farber Cancer Institute. In the Meyerson laboratory, her work focused on understanding the links between tumor suppression and epigenetic mechanisms. Rozenblatt-Rosen earned a B.S. in biology from Tel Aviv University and a Ph.D. from the Weizmann Institute of Science. 


Ilan Schwartz, MD, PhD is an infectious diseases physician and a researcher with an interest in invasive fungal infections. His expertise is in emerging fungal disease and immunocompromised hosts. After completing his clinical training at Queen's University and the University of Manitoba, Dr. Schwartz obtained a Doctorate in Medical Sciences from the University of Antwerp for his investigations into a novel dimorphic fungal genus, Emergomyces. He has since described or co-described several novel, phenotypically distinct pathogenic species within Blastomyces. Dr. Schwartz is a Fellow of the European Confederation of Medical Mycology, and Education Co-Chair for the Mycoses Study Group Education & Research Consortium (MSGERC). 


Lea Starita


Laura Tafe


Koichi Takahashi, MD, PhD is an Assistant Professor of Department of Leukemia and Genomic Medicine MD Anderson Cancer Center. He is a physician scientist specializing on genomics of hematologic malignancies particularly in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and clonal hematopoiesis.  His research focuses on precision characterization of clonal heterogeneity and evolution of leukemia and their clinical implications. 


Scott Topper, PhD is VP of Clinical Operations at Color and oversees Color’s NGS and COVID testing laboratories, the Research and Development organization, the Clinical Genomics teams (variant scientists and medical geneticists), the Genetic Counseling / Pharmacist Services teams and the Client Services. He is an American Board of Medical Genetics and Genomics-certified molecular geneticist, trained at the University of Chicago. He serves on the ClinGen Sequence Variant Interpretation working group and the American College of Medical Genetics Social Ethical and Legal Issues committee. He is also a Principal Investigator on two awards supporting the All of Us Research Program: The Broad-Color-LMM Genome Center Award and the All of Us Research Program Genetic Counseling Resource.

 

Elias I. Traboulsi, M.D., M.Ed.


Anthony (Tony) Tran, DrPH, MPH, D(ABMM), MT(ASCP) received his BS in Medical Technology from the University of Maryland at Baltimore, School of Medicine in 1998, his MPH from the University of Maryland, College Park in 2001, and his DrPH from the University of California, Berkeley in 2013. He completed his ASM CPEP fellowship in medical and public health microbiology from the University of North Carolina, Chapel Hill Health Care System in 2015 and is a Diplomate of the American Board of Medical Microbiology. He has over 15 years of public health and clinical laboratory experience at national, state, and local levels. During the seven years prior to pursing his doctorate, Tony worked at the Association of Public Health Laboratories (APHL), a national nonprofit organization that represents state, territorial and local public health laboratories in the United States. During his seven years at APHL, he led the Association’s efforts on domestic HIV, STD, TB and viral Hepatitis and served on the global health team that works closely with ministries of health all over the world to develop core laboratory infrastructure and build capacity for tests of public health significance. Previously, as Director of Policy and Operations at the New York City Department of Health and Mental Hygiene, Bureau of the Public Health Laboratory, Tony provided guidance and overall direction to all areas of the laboratory including scientific oversight of programs, quality assurance, and laboratory operations. He currently serves as the Director of the District of Columbia Public Health Laboratory, which provides diagnostic testing services for health care providers in the District and surveillance and environmental testing for the DC Department of Health. He is currently leading the District’s testing efforts for COVID-19, in addition to multiple national COVID-19 task forces and also serves on the APHL Board of Directors.


Peter Van Loo, PhD is a group leader at the Francis Crick Institute in London. In his postdoctoral research at the University of Oslo, the University of Leuven, and the Wellcome Trust Sanger Institute, he developed computational techniques to study copy-number alterations in cancer genomes, and approaches to study the subclonal architecture and life history of tumours from whole-genome sequencing data, a field coined “molecular archaeology of cancer”.  Peter’s research leverages massively parallel sequencing efforts to study cancer genes, mutational processes in cancer and tumour evolution. His work has sketched the typical evolutionary trajectories of many cancer types, allowing insight into the timelines of cancer development, as well as insight into how tumours metastasise. Peter is the main lead of Evolution and Heterogeneity working group of the Pan-Cancer Analysis of Whole Genomics (PCAWG) initiative, and the genomics lead of the Sarcoma GeCIP of the 100,000 Genomes Project. Peter has been awarded a Cancer Research UK Future Leaders in Cancer Research Prize in 2015 and a VIB Alumni Award in 2017.


Victor Velculescu


Jinghui Zhang, PhD, is chair of the Department of Computational Biology at St. Jude Children’s Research Hospital. She holds the St. Jude Endowed Chair in Bioinformatics. Computational biology efforts at St. Jude took shape five years ago with the creation of the St. Jude–Washington University Pediatric Cancer Genome Project (PCGP), an unprecedented effort to map the genomes of some of the deadliest childhood cancers. Data generated from the project—100 trillion-plus pieces—encompass the complete normal and cancer genomes of more than 800 children and adolescents with 23 different childhood cancer. Zhang joined St. Jude in 2010, leading the effort to analyze PCGP data and the creation of several new computational tools that have been adopted by researchers worldwide. Her work has helped define the landscape of mutations, leading to new directions in research involving high-risk leukemia, brain and solid tumors. Prior to working at St. Jude, Zhang led genetic variation analysis of the first assembled human genome. She also contributed to key discoveries in the pilot phases of the National Cancer Institute’s Cancer Genome Atlas Project and the Therapeutically Applicable Research to Generate Effective Treatment (TARGET) initiative. Zhang received her undergraduate degree from Fu Dan University in Shanghai and her doctorate from the University of Connecticut in Storrs, Conn.


Justin Zook, PhD, leads the Human Genomics Team at the National Institute of Standards and Technology and is co-leading the Genome in a Bottle Consortium’s work developing authoritatively characterized human genomes to benchmark sequencing methods. He developed methods to compare and integrate whole genome DNA sequencing data from multiple platforms and sequencing runs to characterize the first whole human genome Reference Material. He is now leading the GIAB Analysis Team work combining short, linked, and long read sequencing technologies to characterize structural variation and challenging regions of the genome. He is an Informatics Representative to the Association for Molecular Pathology Clinical Practice Committee. In addition, he was Chair of the Global Alliance for Genomics and Health Benchmarking Team, which recently published best practices for benchmarking genome sequencing results.